Phase 1 clinical trial will evaluate the safety, tolerability, and pharmacokinetics SBS-147 is a novel and potent oral analgesic with a differentiated safety profile being developed for acute and chronic…
Read More
SBS-226 is a dual mu opiate receptor (MOR) partial agonist and delta opiate receptor (DOR) full antagonist in development for opiate use disorder (OUD) and Opiate Withdrawal Syndrome (OWS) Grant…
Read More
Sparian Biosciences, Inc. (“Sparian”), a clinical-stage CNS-focused biopharmaceutical company, is proud to announce formation of a Science Advisory Board (SAB) with the appointments of Eric Nestler, M.D./PhD, Frances Levin M.D.…
Read More
SBS-1000 was shown to be safe and well tolerated in healthy volunteers in this Phase 1 Single Ascending Dose (SAD) study No serious adverse events observed Sedation at higher doses…
Read More
